** CVS Health CVS.N raised its full-year profit forecast on Thursday after beating Wall Street's quarterly earning estimates as tight oversight of higher medical costs improved performance of its Aetna health insurance business
** Rivals including UnitedHealth UNH.N, Elevance ELV.N and Centene CNC.N have warned of higher-than-expected medical costs in the second-quarter.
** 20 out of 29 analysts rate stock as buy or higher, 9 hold; Median PT is $80 - LSEG
CVS HEALTH ON THE RIGHT TRACK
** Evercore ISI ("outperform," PT: $85) says CVS is moving with clearer operational focus and sharper discipline under new management
** Leerink Partners ("outperform," PT: $86) says majority of the moving parts in the health care benefits segment are on the right track
** "We continue to see more tailwinds than headwinds" - brokerage
** Morningstar (fair value: $92) says CVS's profit forecast raise sets it apart from peers like CNC, ELV and UNH that cut 2025 guidance after weak results
** TD Cowen ("buy," PT: $95) says they believe second-half guidance still has room for upside
(Reporting by Twesha Dikshit)
((Twesha.Dikshit@thomsonreuters.com))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。